https://newsletter.glp1studio.com/p/keeping-weight-off-after-semaglutideGLP-1 Studioen2026-09-25T17:00:00+00:00Keeping weight off after semaglutide may need a second drughttps://newsletter.glp1studio.com/p/what-the-fdas-compounding-crackdownGLP-1 Studioen2026-09-25T17:00:00+00:00What the FDA's compounding crackdown means for your GLP-1 supplyhttps://newsletter.glp1studio.com/p/novos-investor-day-disappoints-asGLP-1 Studioen2026-09-24T17:00:00+00:00Novo's investor day disappoints as Lilly widens its leadhttps://newsletter.glp1studio.com/p/a-chinese-drugmakers-obesity-dataGLP-1 Studioen2026-09-24T17:00:00+00:00A Chinese drugmaker's obesity data will invite a semaglutide comparison